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The cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved 
antigen involved in sporozoite motility, plays an important role in the traversal of host cells 
during the preerythrocytic stage of Plasmodium species. Recently, it has been considered 
an alternative target when designing novel antimalarial vaccines against Plasmodium 
falciparum. However, the potential of Plasmodium vivax CelTOS as a vaccine target is 
yet to be explored. This study evaluated the naturally acquired immune response against 
a recombinant P. vivax CelTOS (PvCelTOS) (IgG and IgG subclass) in 528 individuals 
from Brazilian Amazon, as well as the screening of B-cell epitopes in silico and peptide 
assays to associate the breadth of antibody responses of those individuals with exposi-
tion and/or protection correlates. We show that PvCelTOS is naturally immunogenic in 
Amazon inhabitants with 94 individuals (17.8%) showing specific IgG antibodies against 
the recombinant protein. Among responders, the IgG reactivity indexes (RIs) presented 
a direct correlation with the number of previous malaria episodes (p = 0.003; r = 0.315) 
and inverse correlation with the time elapsed from the last malaria episode (p = 0.031; 
r = −0.258). Interestingly, high responders to PvCelTOS (RI > 2) presented higher number 
of previous malaria episodes, frequency of recent malaria episodes, and ratio of cytophilic/
non-cytophilic antibodies than low responders (RI < 2) and non-responders (RI < 1). 
Moreover, a high prevalence of the cytophilic antibody IgG1 over all other IgG subclasses 
(p < 0.0001) was observed. B-cell epitope mapping revealed five immunogenic regions 
in PvCelTOS, but no associations between the specific IgG response to peptides and 
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inTrODUcTiOn
Malaria remains a major public health problem worldwide. It is 
caused by protozoan parasites of the genus Plasmodium, being 
responsible for nearly 438,000 deaths and 150–300 million new 
infections in 2015 (1) and the reason of enormous socioeconomic 
impact in endemic settings (2). Among the Plasmodium species 
able to infect humans, Plasmodium falciparum and Plasmodium 
vivax are the most prevalent malaria parasites. P. falciparum is 
extremely prevalent in Africa and is responsible for the major-
ity of cases and deaths worldwide, while P. vivax is the most 
prevalent species outside Africa (3). Despite the reduction in the 
number of malaria cases and deaths over the past decade (1), the 
emergence of drug resistance and the significant ongoing burden 
of morbidity and mortality emphasize the need for an effective 
malaria vaccine. Unfortunately, potential P. vivax vaccine candi-
dates lag far behind those for P. falciparum (4). Currently, besides 
the RTS, S vaccine, there are 30 candidate vaccine formulations 
in clinical trials against P. falciparum, while there is only one 
against P. vivax (5). These data allied to the impact caused by the 
high P. vivax prevalence (2), the severity of the disease (6–11), 
and the emergence of strains resistant to chloroquine (12–14) 
and primaquine (15–17), reiterate the importance of identifying 
and exploring the potential of vaccine candidates against P. vivax 
as an essential step in the development of a safe and affordable 
vaccine.
Malaria liver-stage vaccines are one of the leading strategies 
and the only approach that has demonstrated complete, sterile 
protection in clinical trials. Therefore, vaccines targeting sporo-
zoite and liver-stage parasites, when parasite numbers are low, 
can lead to the elimination of the parasite before it advances to 
the symptomatic stage of the disease (18). Corroborating this 
idea, the sterile protection against P. falciparum by immuniza-
tion with radiation-attenuated sporozoites was demonstrated 
in several studies (19–21) and the protection lasted for at least 
10  months and extended to heterologous strain parasites (22). 
Based on these findings, sporozoite surface antigens are one of 
the most promising vaccine targets against malaria, to protect 
and prevent the symptoms and block its transmission. To date, 
RTS,S, the subunit vaccine consisting of a portion of P. falciparum 
circumsporozoite protein (CSP), conferred partial protection in 
Phase III trials and fell short of community-established vaccine 
efficacy goals (23–26). Conversely, Gruner and collaborators 
have demonstrated that the sterile protection against sporozoites 
can be obtained in the absence of specific immune responses to 
CSP (27). In addition, a recent study found 77 parasite proteins 
associated with sterile protection against irradiated sporozoites 
(28). Collectively, these data reinforce the concept that a multi-
valent anti-sporozoite vaccine targeting several surface-exposed 
antigens would induce a higher protection efficacy.
In this scenario, cell-traversal protein of Plasmodium ookinetes 
and sporozoites, a highly conserved protein among Plasmodium 
species, emerged as a novel target in the development of a vaccine 
against Plasmodium parasites (29). This secretory microneme 
protein is translocated to the sporozoites and ookinetes surface, 
being necessary for sporozoites and ookinetes to break through 
cellular barriers and establish infection in the new host, having 
a crucial role on cell-transversal ability in both stages (29, 30). 
The disruption of the genes encoding CelTOS in Plasmodium 
berghei reduces the infectivity in the mosquito host and also 
the infectivity of the sporozoite in the liver, almost eliminating 
their ability to cell pass (29). Interestingly, P. falciparum CelTOS 
(PfCelTOS) was naturally recognized by acquired antibodies in 
exposed populations (31), able to induce cross-reactive immunity 
against P. berghei and inhibit sporozoite motility and invasion of 
hepatocytes in vitro (32). However, the knowledge about P. vivax 
CelTOS (PvCelTOS) has remained limited. Only recently, a 
study reported PvCelTOS as naturally immunogenic in infected 
individuals from Western Thailand. Our group, investigating the 
genetic diversity of genes encoding PvCelTOS in field isolates 
from five different regions of the Amazon forest, reveals a high-
conserved profile. Together, both findings support the potential of 
PvCelTOS as an interesting target on P. vivax sporozoite surface, 
but further studies are still necessary to consolidate this protein 
as an alternative in future multitarget vaccines. Therefore, the 
present study aimed at evaluating the naturally acquired humoral 
immune response against PvCelTOS in exposed populations 
from Brazilian Amazon, determining the antibody subclass 
profile, identifying its B-cell epitopes and verifying the existence 
of associations between the specific IgG and subclass response 
against PvCelTOS and epidemiological data that can reflect the 
exposition and/or protection degree.
ParTiciPanTs anD MeThODs
study area and Volunteers
A cross-sectional cohort study was conducted involving 528 indi-
viduals from Rio Preto da Eva (2°50′50″S/59°56′28″W), located 
north of the Amazon River and 80  km distant from Manaus, 
the capital of Amazon state. This city has an area of 6,000 km2 
exposure/protection parameters were found. However, the epitope (PvCelTOSI136-E143) 
was validated as a main linear B-cell epitope, as 92% of IgG responders to PvCelTOS 
were also responders to this peptide sequence. This study describes for the first time the 
natural immunogenicity of PvCelTOS in Amazon individuals and identifies immunogenic 
regions in a full-length protein. The IgG magnitude was mainly composed of cytophilic 
antibodies (IgG1) and associated with recent malaria episodes. The data presented in 
this paper add further evidence to consider PvCelTOS as a vaccine candidate.
Keywords: PvcelTOs, P. vivax, vaccines, epitope mapping, epitope prediction, malaria vaccines, malaria
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and a population of about 22,000 people, who live in rural areas 
inside the forests. Transmission of malaria in the Amazon occurs 
throughout the whole year, with seasonal fluctuations with maxi-
mum transmission occurring during the dry season from May to 
October and prevalence of infections by P. vivax, responsible for 
more than 85% of reported malaria cases.
Samples and survey data were collected from November 
2013 to March 2015. In addition, we also included, as control 
subjects, 10 naive individuals living in Manaus, and with no 
reported previous malaria episodes. Written informed consent 
was obtained from all adult donors or from parents of donors 
in the case of children. The study was reviewed and approved by 
the Fundação Oswaldo Cruz Ethical Committee and the National 
Ethical Committee of Brazil.
epidemiological survey
In order to evaluate the possible influence of epidemiological 
factors on humoral immunity against PvCelTOS, all donors were 
interviewed upon informed consent prior to blood collection. 
The survey included questions related to personal exposure to 
malaria, such as years of residence in the endemic area, recorded 
individual and family previous malaria episodes, use of malaria 
prophylaxis, presence/absence of symptoms, and personal 
knowledge of malaria transmission. All epidemiological data 
were stored in Epi-Info for subsequent analysis (Centers for 
Disease Control and Prevention, Atlanta, GA, USA).
Malaria Diagnosis and Blood sampling
Venous peripheral blood was drawn into heparinized tubes and 
plasma collected after centrifugation (350 × g, 10 min). Plasma 
samples were stored at −20°C and transported to our labora-
tory. Thin and thick blood smears of all donors were examined 
for malaria parasites. Parasitological evaluations were done by 
examination of 200 fields at 1,000× magnification under oil-
immersion and a research expert in malaria diagnosis examined 
all slides. Donors positive for P. vivax and/or P. falciparum at 
the time of blood collection were subsequently treated using 
the chemotherapeutic regimen recommended by the Brazilian 
Ministry of Health.
recombinant PvcelTOs expression in 
heK-293T cells
As previously described (33), the P. vivax sequence for CelTOS 
(Salvador I; Uniprot accession number Q53UB7) was cloned in 
the expression vector pHLsec, which is flanked by the chicken 
β-actin/rabbit β-globin hybrid promoter with a signal secretion 
sequence and a Lys-His6 tag. The protein was expressed upon 
transient transfection in HEK-293T cells with endotoxin-free 
plasmids in roller bottles (2,125 cm2). The secreted protein was 
purified from the supernatant by immobilized Ni Sepharose 
affinity chromatography. The presence of proteins in the elu-
tion samples was confirmed using 6xHis epitope tag antibody 
[horseradish peroxidase (HRP) conjugate] in a Western blot. 
The sample was concentrated using an Amicon Ultra centrifugal 
filter system (Life Technologies) until reaching 10  ml of final 
volume. Contaminant proteins and salts were removed from the 
concentrate by size exclusion purification (SEC) using Superdex 
medium in the column. Protein concentration after recovery was 
tested using a Bradford protein assay, and purity was assessed by 
silver staining and by Western blotting.
antibody assays
Anti-PvCelTOS specific antibodies were evaluated on plasma 
samples from 528 exposed individuals from Brazilian Amazon 
and 10 healthy individuals, who had no reported malaria 
episodes, using enzyme-linked immunosorbent assay (ELISA), 
essentially as previously described (33, 34). Briefly, MaxiSorp 
96-well plates (Nunc, Rochester, NY, USA) were coated with PBS 
containing 1.5  µg/ml of recombinant protein. After overnight 
incubation at 4°C, the plates were washed and blocked for 1 h 
at 37°C. Individual plasma samples diluted 1:100 in PBS-Tween 
containing 5% non-fat dry milk (PBS-Tween-M) were added 
in duplicate wells. After 1  h at 37°C and three washings with 
PBS-Tween, bound antibodies were detected with peroxidase-
conjugated goat antihuman IgG (Sigma, St. Louis) and followed by 
addition of o-phenylenediamine and hydrogen peroxide. Optical 
density was identified at 492 nm using a SpectraMax 250 ELISA 
reader (Molecular Devices, Sunnyvale, CA, USA). The results for 
total IgG were expressed as reactivity indexes (RIs), which were 
calculated by the mean optical density of an individual’s tested 
sample divided by the mean optical density of 10 non-exposed 
control individuals’ samples plus 3 standard deviations. Subjects 
were scored as responders to PvCelTOS if the RI of IgG against 
the recombinant protein was higher than 1. Additionally, the RIs 
of IgG subclasses were evaluated on responders individuals by 
a similar method, using peroxidase-conjugated goat antihuman 
IgG1, IgG2, IgG3, and IgG4 (Sigma, St. Louis).
B cell epitope Prediction on PvcelTOs
The prediction of linear B-cell epitopes was carried out using the 
program BepiPred (35), which is based on hidden Markov model 
profiles of known antigens, and also incorporates hydrophilic-
ity and secondary structure prediction. For each input FASTA 
sequence, the server outputs a prediction score for each amino 
acid. The recommended cutoff of 0.35 was used to determine 
potential B-cell linear epitopes, ensuring sensibility of 49% and 
specificity of 75% to this approach. Linear B-cell epitopes are 
predicted to be located at the residues with the highest scores. 
In this study, BepiPred was used to predict B-cell linear epitopes 
and to evaluate the prediction value of peptides containing short 
amino acid sequences of PvCelTOS.
The Emini surface accessibility (ESA) was used to evaluate the 
probability of predicted linear B-cell epitopes to be exposed on 
the surface of the protein. This approach calculates the surface 
accessibility of hexapeptides and values greater than 1.0 indicate 
an increased probability of being found on the surface (36). 
Sequences with BepiPred score above 0.35 and ESA score above 
1.0 were considered potential linear B-cell epitopes in regions that 
could be accessed by naturally acquired antibodies.
B-cell epitope Mapping of PvcelTOs
A peptide library of 32 PvCelTOS synthetic 15-mer peptides over-
lapping by nine amino acids (GenOne Biotechnologies; purity 
95% based on HPLC) was synthesized. To evaluate the specific 
TaBle 1 | summary of the epidemiological data of the studied 
population.
Overall PvcelTOs igg 
responders
PvcelTOs 
igg non-
responders 
(nrs)
gender—N (%)
Male 284 (53.8%) 55 (58.5%) 229 (52.8%)
Female 244 (46.2%) 39 (41.5%) 205 (47.2%)
Total 528 94 434
Malaria exposure—median (ir)
Age (years) 36 (25–50) 38 (21–55.5) 36 (21–50)
Time of residence in endemic 
area (years)
33 (19–49) 35 (21–55) 33 (19–48)
Number of previous malaria 
episodes (n)
4 (2–10) 4.5 (2–10) 4 (2–10)
Time since the last malaria 
episode (months)
51 (24–91) 60 (13.7–89.2) 51 (24–90.5)
Frequency of recent malaria 
episodes (%)
12.7% 16.0% 13.1%
Previous malaria species contracted—N (%)
Never infected 7 (1.3%) 0 (0%) 7 (1.6%)
Plasmodium falciparum 32 (6.1%) 5 (5.3%) 27 (6.2%)
Plasmodium vivax 125 (23.7%) 25 (26.6%) 100 (23%)
Both species 158 (29.9%) 31 (33%) 127 (29.3)
Not reported/remember 206 (39%) 33 (35.1%) 173 (39.9%)
Values of age, time of residence in endemic areas, number of previous malaria 
episodes, and time elapsed from the last malaria episode represent the median 
(interquartile range), while the parameter “frequency of recent malaria episodes” 
represents the percentage of individuals who reported malaria episode in the last year. 
The frequency of individuals who present recent malaria episodes was compared by 
Fisher’s test, and other epidemiological parameters were compared by Mann–Whitney 
test. No statistical difference was observed between epidemiological parameters of 
responders and NR individuals.
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response to each peptide, the peptide array was performed using 
MaxiSorp 96-well plates (Nunc, Rochester, NY, USA) coated 
with PBS containing 5 µg/ml of each peptide in duplicates. After 
overnight incubation at 4°C, the plates were washed with PBS 
and blocked with PBS-Tween containing 5% non-fat dry milk 
(PBS-Tween-M) for 1 h at 37°C. Individual plasma samples were 
diluted 1:100 with PBS-Tween-M and added in duplicate wells 
for each sequence and the plates incubated at room temperature 
for 1 h. After three washings with PBS-Tween, bound antibodies 
were detected with peroxidase-conjugated goat antihuman IgG 
(Sigma, St. Louis) followed by addition of o-phenylenediamine 
and hydrogen peroxide. The absorbance was read at 492 nm using 
an ELISA reader (Spectramax 250, Molecular Devices, Sunnyvale, 
CA, USA). The results for total IgG were expressed as RIs, which 
were calculated by the mean optical density of the tested samples 
plus 3 standard deviations of pools of control individuals. Subjects 
were scored as positive if the RI was higher than 1.
root Mean square Fluctuation (rMsF) and 
electrostatic Potential surface calculation
Molecular dynamics simulations were carried out using 
GROMACS 5.1.2 (37) software package. Gromos53a6 (38) force 
field was used. Simple point charge water model (39) was used 
to solvate the system. Charges were neutralized using Na+ and 
Cl− ions. Steepest descent method was used for energy minimi-
zation. Further, 100 ps temperature equilibration was carried out 
at a temperature of 300 K in the presence of position restraints 
of 1,000 KJ/mol and the pressure coupling of 1,000 ps at 1 bar 
of atmospheric pressure. After equilibration, the simulation of 
200,000 ps (200 ns) without position restraints was carried out. 
All simulations were run three times, and consistent results were 
recorded. RMSF was analyzed from simulation trajectory using 
GROMACS utilities. The Electrostatic potential surface for the 
PvCelTOS was calculated using APBS (40) and visualized in 
PyMOL (Pymol LLC) and the electrostatic potential surfaces for 
the contours from −3kT/e (red) to +3kT/e (blue) were visualized. 
The figures were rendered using PyMol.
statistical analysis
All statistical analyzes were carried out using Prism 5.0 
for Windows (GraphPad Software, Inc.). The one-sample 
Kolmogorov–Smirnoff test was used to determine whether a 
variable was normally distributed. The Mann–Whitney test was 
used to compare RIs of IgG against recombinant PvCelTOS 
between studied groups. Differences in proportions of the RI of 
IgG subclasses and epidemiological parameters were evaluated by 
Fisher’s exact test and associations between antibody responses 
and epidemiological data were determined by Spearman rank 
test. A two-sided p value <0.05 was considered significant.
resUlTs
epidemiological Profile of studied 
individuals
Most studied individuals were adults and naturally exposed to 
malaria infection throughout the years (Table  1). Age ranged 
from 10 to 89 years with an average of 36.9. The proportion of 
men was significantly higher (53.8%) than for women (46.2%; 
χ2 = 5.761, p < 0.0164). Regarding the previous personal history 
of malaria, only seven individuals reported no malaria episode 
(1.3%). Among those who remembered the Plasmodium species, 
the majority (29.9%) reported infections by P. falciparum and P. 
vivax. The number of past malaria episodes also varied greatly 
among donors, ranging from 0 to 50 (mean =  7.74  ±  16.5). 
Finally, the time elapsed since the last malaria episode ranged 
from 0 to 480  months (mean =  71.7 ±  77.9). Interestingly, a 
correlation trend was observed between the time of residence in 
the endemic area and the number of previous malaria infections 
(p = 0.0003; r = 0.153). Collectively, the epidemiological inquiry 
indicated that the studied population had different degrees of 
exposure and/or immunity.
PvcelTOs is naturally immunogenic with 
the Prevalence of cytophilic antibodies in 
Brazilian amazon individuals
To test if the PvCelTOS is a target for naturally acquired 
antibodies in Amazon individuals, we first assessed the IgG 
reactivity profile against the recombinant protein. The plasma 
samples collected from the 528 individuals living in the endemic 
area reveal a low frequency of responders to PvCelTOS, since 
only 17.8% of the studied population (94 individuals) presented 
FigUre 1 | reactivity index (ri) of igg and subclass against PvcelTOs. On both graphs, each point represents an individual RI against PvCelTOS and the 
red traced line represents the cutoff. Ninety-four individuals presented RI against PvCelTOS higher than 1 and were considered responders to this protein. Among 
the responders, IgG1 was the prevalent subclass in comparison to IgG2 (p = 0.0012), IgG3 (p < 0.0001), and IgG4 (p < 0.0001). Additionally, the RI of IgG1 was 
higher than the RI of all other subclasses (p < 0.0001), and the RI of IgG4 was statistically lower than all other subclasses (p < 0.0001).
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specific IgG antibodies against the protein. Interestingly, the 
epidemiological data were similar between responders and NRs 
against this protein (Table 1). On both groups, responders and 
NRs, the age, time of residence in endemic area, the number of 
previous malaria episodes, the number of recent malaria epi-
sodes, the frequency of individuals with recent malaria episodes, 
and months elapsed from the last malaria episode were similar 
(p > 0.05).
Among the group of responders to PvCelTOS, the RI 
ranged from 1.01 to 19.93 (median  =  1.205; interquartile 
range = 1.082; 1.552), reflecting a wide spectrum in magnitude 
of naturally acquired IgG response. The IgG subclass profile 
was marked by IgG1, the most prevalent subclass, present in 
65.96% of responders, and with major RI (median = 1.15; inter-
quartile range = 0.86–1.68) compared to IgG2 (median = 0.9; 
interquartile range  =  0.66–1.2), IgG3 (median  =  0.88; 
interquartile range =  0.72–1.06), and IgG4 (median =  0.62; 
interquartile range =  0.51–0.76) (Figure  1). Moreover, IgG3 
RIs were directly correlated to the number of recent malaria 
episodes (p = 0.003; r = 0.315; Figure S1A in Supplementary 
Material) and inversely associated with the time elapsed from 
the last malaria episode (p = 0.031; r = −0.258; Figure S1B in 
Supplementary Material).
high igg ris against PvcelTOs are Driven 
by cytophilic antibodies and associated 
with recent infections
In order to identify possible factors that could be associated with 
this large spectrum of reactivity against PvCelTOS in IgG-positive 
individuals, we explored epidemiological data among respond-
ers. Initially, we observed that the RI against PvCelTOS was 
directly correlated with the number of previous malaria 
episodes (p =  0.047; r =  0.227; Figure S1C in Supplementary 
Material) and inversely correlated with the time elapsed from 
the last malaria episode (p =  0.045; r = −0.24; Figure S1D in 
Supplementary Material). Based on these findings, responder 
individuals were divided into two subgroups: high responders 
(HRs; individuals who had RI of IgG against PvCelTOS higher 
than 2) and low responders (LRs; individuals who had RI of IgG 
against PvCelTOS between 1 and 2). Figure  2A illustrates the 
means of epidemiological parameters of HRs, LRs, and NRs to 
PvCelTOS. Interestingly, while NRs and LRs presented a very 
similar profile of epidemiological parameters, HRs presented 
a statistically higher number of previous malaria episodes in 
comparison to NR and LR (p = 0.0058; p = 0.0051, respectively). 
Moreover, despite no statistical differences could be observed 
on the time elapsed from the last malaria episode (p =  0.15 
in ANOVA test), the frequency of individuals who reported 
recent episodes of malaria was higher in HR (41.6%) than LR 
(12%, p  =  0.02) and NR (13.1%, p  =  0.016). Moreover, the 
proportion of RIs of cytophilic over non-cytophilic antibodies 
(IgG1 + IgG3/IgG2 + IgG4) presented direct correlation with RI 
of IgG of responder individuals (p = 0.0016; r = 0.32), suggesting 
that higher RI could be associated with a cytophilic profile of 
humoral response against PvCelTOS. Interestingly, although the 
proportion of individuals with cytophilic profile was similar in 
both groups, HR and LR (83% and 78%, respectively), the ratio of 
(cytophilic/non-cytophilic) antibodies was significantly higher 
in HR than LR (p = 0.0076) (Figure 2B).
FigUre 2 | comparison of profiles of high responders (hrs), low responders (lrs), and non-responders (nrs) to PvcelTOs. (a) Diagram of 
epidemiological data. The mean values of epidemiological parameters of HRs, LRs, and NRs to PvCelTOS are represented by red, blue, and yellow areas, 
respectively. Age and time of residence in endemic areas are expressed in years, while time elapsed from the last malaria episode is expressed in months and 
frequency of recent malaria episodes indicates the percentage of individuals who reported malaria episodes in the last year. HRs presented a higher number of 
previous malaria episodes and higher frequency of recent malaria episodes than LRs (p = 0.0051 and p = 0.02, respectively) (B) Comparison of ratio (cytophilic/
non-cytophilic) antibodies. Red and blue points represent the HR and LR, respectively. Points above the value of 1 represent individuals with a cytophilic profile of 
IgG (IgG1 + IgG3, higher than IgG2 + IgG4).
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Five immunogenic regions identified in 
PvcelTOs and Two linear B-cell epitopes 
Broadly recognized by naturally acquired 
igg antibodies
Four B-cell linear epitopes were predicted in silico in the entire 
sequence of PvCelTOS (PvCelTOSK6-N13; PvCelTOSG38-R57; 
PvCelTOSI136-E143; PvCelTOSK166-S191).
In order to validate the prediction data and identify pos-
sible non-predicted immunogenic regions of PvCelTOS, 
plasma from IgG responders to PvCelTOS was tested against 
32 overlapping peptides corresponding to the complete amino 
acid sequence. First, 10 peptides (N13-L27; S19-V33; E73-I87; 
L79-K93; S97-A111; P127-V141; I133-G147; P139-V153; 
L181-L195; E182-D196) were broadly recognized by respond-
ers to PvCelTOS (Figure  3). Two of the predicted epitopes 
(PvCelTOSI136-E143 and PvCelTOSK166-S191) were present (partially 
or entirely) in peptides confirmed as naturally immunogenic. 
Interestingly, peptides I133-G147 and E182-D196 were recog-
nized by IgG specific antibodies of responders to PvCelTOS 
in frequencies higher than 50% (92% and 54%, respectively) 
and presented median of RI higher than 1 (1.79 and 1.14, 
respectively). In addition, peptides P127-V141, P139-V153, 
and L181-L195 were located besides the most immunogenic 
peptides and presented overlapped sequences, which were also 
recognized by IgG antibodies in moderate frequencies. Peptide 
I133-G147 (ASTIKPPRVSEDAYF) presented the highest IgG RI 
(p < 0.0001 by ANOVA test) and the highest frequency of rec-
ognition (92%) compared to all other peptides. While it contains 
the entire sequence of predicted epitope PvCelTOS136-143, pep-
tides P127-V141 and P139-V153, which contain only the partial 
sequence of the predicted epitope, presented minor frequencies 
of recognition (38% and 39%, respectively; p < 0.0001 on Fisher’s 
exact test). The peptides L181-L195 and 186-196 were both 
partially inserted in the predicted linear epitope PvCelTOS166-191 
and could be the immune dominant sequence of this longer 
predicted epitope. These data supported the prediction of 
linear B-cell epitopes PvCelTOSI136-E146 and PvCelTOSK166-S191. 
Conversely, peptides N13-L27, S19-V33, and S97-A111 also 
presented frequency of recognition about 40% (38, 40, and 
36%, respectively). After the confirmation of five immunogenic 
regions and two immunodominant epitopes in PvCelTOS, we 
also compared the RI and frequencies between HR and LR for 
PvCelTOS. However, no differences were found.
Main B cell epitopes are Present on 
PvcelTOs surface
Peptides that presented overlapped amino acids and were 
recognized by more than 20% of responders to PvCelTOS 
(Figure  3) were grouped as immunogenic regions. All pep-
tides inserted in identified immunogenic regions are listed 
in Table  2 with their respective frequencies of recognition, 
BepiPred and ESA scores. In this context, we identified five 
immunogenic regions PvCelTOSN13-V33, PvCelTOSE73-K93, 
PvCelTOSS97-A111, PvCelTOSP127-V153, and PvCelTOSL181-D196, in 
which B-cell epitopes could be inserted. Interestingly, the pep-
tides with higher frequency of specific responders (I133-G147, 
L181-L195, and 182-186) presented a good combination 
of BepiPred and ESA score. The molecular dynamics and 
electrostatic potential surface of PvCelTOS indicate regions 
P127-V153, N13-V33, and L181-D186 as more flexible than 
E73-K93 and S97-A111 (Figure 4A). Regarding solvent expo-
sure, all immunogenic regions were exposed and accessible in 
solution. Interestingly, the immunogenic regions L181-D196 
and E73-K93 are part of a very negatively charged region, 
while N13-V33 and P127-V153 are in a mostly neutral-positive 
region (Figure 4B).
FigUre 3 | Mapping of B-cell epitopes in PvcelTOs. Each column represents a peptide, the numbers indicate the first and last amino acid (aa-aa) of the 
peptide. The points represent the value of IgG reactivity index (RI) specific for each peptide of one responder to PvCelTOS and the red traced line represents the 
cutoff value. The black lines indicate median and interquartile range. If the RI for one peptide was higher than 1, the individual was considered positive to this 
peptide. The white bar on top represents the linear structure of the protein, in which the blue boxes indicate the BepiPred prediction score and red boxes indicate 
the Emini surface accessibility score of predicted linear epitopes.
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DiscUssiOn
Despite significant advances in the understanding of the biol-
ogy of Plasmodium parasites and the immune response elicited 
by these pathogens, there is not yet a subunit vaccine capable 
of providing long-lasting protection. The cell-traversal protein 
for ookinetes and sporozoites (CelTOS) has been considered a 
potential novel alternative for a vaccine against malaria (29, 32, 
41), but the knowledge on P. vivax CelTOS potential remains 
scarce. Unfortunately, many conventional vaccinology strategies 
applied to P. falciparum are especially difficult when dealing with 
non-cultivable microorganisms such as P. vivax. Consequently, 
seroepidemiological studies have played a significant role in 
the identification and validation of P. vivax vaccine candidates 
(42–48). Therefore, we confirmed the naturally acquired 
humoral response against PvCelTOS (IgG and IgG subclass) and 
identified five B-cell epitopes along the entire PvCelTOS amino 
acid sequence, which were recognized by IgG antibodies from 
malaria-exposed populations from Brazilian Amazon.
Plasma samples were collected in three cross-sectional studies 
with Brazilian Amazon communities between 2013 and 2015. 
The profile of the studied individuals shows that our population 
included rainforest region natives and migrants from non-
endemic areas of Brazil who had lived in the area for more than 
10 years. The majority of individuals reported a prior experience 
with P. vivax and/or P. falciparum malaria. Concerning malaria 
history, the highly variable range of number of previous infec-
tions, time of residence in endemic areas, and time since the last 
infection suggests differences in exposure and immunity, since it 
is well known that the acquisition of clinical immunity mediated 
by antibodies depends on continued exposure to the parasite 
(49–51). The correlation between time of residence in endemic 
areas and months since the last infection observed in our study 
also indicates that this phenomenon could be occurring in low/
medium endemic areas like the Brazilian Amazon. Therefore, the 
selection of these individuals was ideal to detect the presence of 
antibodies against the new recombinant antigen and distinguish 
whether the alterations found were related to malaria exposure 
and/or indicatives of protection.
First, we found 94 individuals presenting specific antibodies 
to PvCelTOS and confirmed the natural immunogenicity of 
PvCelTOS among exposed individuals from Brazilian Amazon. 
Recently, Longley and collaborators also reported the first 
evidence of naturally induced IgG responses to PvCelTOS in 
human volunteers from Western Thailand (33). Interestingly, 
the frequency of responders to PvCelTOS observed in our stud-
ied population (17.8%) was similar to the frequency observed 
by Longley on uninfected and clinical malaria individuals (33). 
Moreover, the low humoral reactivity against PvCelTOS is 
commonly found in other Plasmodium preerythrocytic antigens 
(48, 52, 53). The short life of specific antibodies, host genetic 
factors, and/or epidemiological parameters could be possible 
reasons for the low frequency of responders against PvCelTOS 
in endemic areas. The short life of specific PvCelTOS humoral 
response hypothesis does not seem to occur since Longley et al. 
verified that IgG positivity and magnitude of response were 
present over the 1-year period in the absence of P. vivax infec-
tions (33). Our study also describes anti-PvCelTOS antibodies 
in individuals who reported no malaria in the last 10 years or 
more. However, in both cases, the contact between human host 
and sporozoite antigens in transmission areas was not evaluated. 
In relation to host genetic factors, there is a significant body of 
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evidences of its influence in malaria outcomes and the capac-
ity to mount a humoral immune response (54–57). To date, 
associations of HLA class II on humoral immune response to 
malaria antigens were reported in individuals living in malaria-
endemic areas from Brazilian Amazon (58, 59) and in human 
vaccine trials (60–62). In P. vivax preerythrocytic targets, the 
presence of HLA-DRB1*03 and DR5 was associated with the 
absence of antibody response to the CSP amino-terminal region 
(48) and HLA-DRB1*07 was related to the absence of specific 
antibodies for CSP repeats of VK210 (52). Moreover, Chaves and 
collaborators reported that PvCelTOS gene sequence is highly 
conserved among isolates from different Brazilian geographic 
regions (unpublished data), suggesting a low selective pressure 
by immune response against PvCelTOS. In our view, the influ-
ence of immunogenetic factors in PvCelTOS-specific humoral 
response are feasible, but more studies are still necessary to 
confirm this hypothesis.
Regarding the influence of epidemiological factors, we initially 
tried to investigate the associations between exposition to malaria 
and the frequency of IgG responders to PvCelTOS. Surprisingly, 
although the association of epidemiological data with specific 
response against Plasmodium antigens was well characterized on 
several studies (63–65), we observed a similar epidemiological 
profile between responders and NRs to PvCelTOS. Therefore, 
we focused on the search of distinct epidemiological and IgG 
subclass profiles among PvCelTOS responder individuals. The 
knowledge about the antibody subclass profile is critical to sug-
gest functional antimalarial immunity and to evaluate potential 
vaccine candidates. Cytophilic antibodies (IgG1 and IgG3) are 
frequently prevalent on immune serum from high-transmission 
areas (66–69) and often correlate with protection from disease 
(70–72). In our study, IgG1 presented higher frequencies of 
responders and median RI than all other subclasses. Moreover, 
IgG3 RIs were directly associated with the number of malaria 
episodes over the last 12 months and inversely correlated with 
the time elapsed from the last malaria episode, suggesting that 
recent P. vivax infections can raise the levels of anti-PvCelTOS 
specific IgG3. The sterile protective immunity to malaria was 
recently associated with a panel of antigens (28), and the relation-
ship of cytophilic antibodies and reduced risk of symptoms are a 
common finding in high endemic areas (70–74). However, in our 
study, concerning the higher levels of IgG1 for PvCelTOS and 
the association of IgG3 levels with recent infections, we cannot 
confirm or discard its role as part of protective humoral response 
until more conclusive studies, such as sporozoite inhibition by 
anti-PvCelTOS specific antibodies, are conducted. In the same 
way, among responders, IgG RIs were directly correlated with the 
number of previous malaria episodes and inversely correlated 
with the time elapsed from the last malaria episodes, suggesting 
that antibody levels for PvCelTOS could be associated with recent 
infections.
The influence of epidemiological parameters on immunity 
to malaria was previously observed in studies from Brazilian 
Amazon population. Based on previous studies that associated 
high levels of antibodies with multiple preerythrocytic antigens 
with reduced risk of clinical malaria in children (75) and decreased 
risk of infection in adults (68), we also aimed to investigate if 
FigUre 4 | Molecular dynamics and electrostatic potential surface for the PvcelTOs. (a) Sausage plot of the PvCelTOS. The red color identifies the 
immunogenic regions of PvCelTOS. Thickness depicts relative fluctuation as calculated during molecular dynamics. The thinnest segments represent the most 
stable regions of the protein. (B) The surface model shows the electrostatic potential surface of the PvCelTOS, representing the positive (blue) and negative (red) 
charges. The secondary structure in the background represents the immunogenic region.
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the epidemiological parameters could reveal new findings about 
the role of exposition on PvCelTOS immunogenicity. Therefore, 
we subdivided the large spectrum IgG RIs among PvCelTOS 
responders into HRs (RI > 2) and LRs (RI < 2). Although LRs 
and NRs to PvCelTOS presented similar exposition factors to 
malaria, interestingly, HR individuals presented a remarkable 
higher number of previous malaria episodes, frequency of recent 
malaria episodes, and a higher ratio of cytophilic/non-cytophilic 
antibodies than LRs. This observation suggested that higher 
level of exposition to malaria induced a more intense and 
improved humoral response against PvCelTOS. Unfortunately, 
the cross-sectional design of our study limited the investigation 
to retrospective malaria histories, and the best approximation 
of an individual’s protection was the estimated amount of time 
that had passed since their last malaria episode, which presented 
no significant association with IgG response against PvCelTOS. 
Prospective studies on humoral immune responses and studies 
addressing the ability of these antibodies to interfere the motility/
invasion of sporozoites (76, 77) will provide more evidences of 
the protective role of anti-PvCelTOS antibodies.
Information at the amino acid level about the epitopes of pro-
teins recognized by antibodies is important for their use as bio-
logical tools and for understanding general molecular recognition 
events (78). In this context, epitope prediction programs have been 
widely used in malaria research (4, 79–81). Nevertheless, the use 
of chemically prepared arrays of short peptides is a more powerful 
tool to identify and characterize epitopes recognized by antibodies 
(46, 82, 83). It is also important to mention that in order to raise 
antibodies for a peptide, a minimum length of six amino acids is 
required, and peptides of >10 amino acids are generally required 
for the induction of antibodies that may bind to the native protein 
(84). In this context, the synthesis of 15 amino acid peptides, with 
9 overlapping, has allowed the identification of PvCelTOS B-cell 
epitopes encompassed in sequences ranging from 15 to 27 amino 
acids in length. Therefore, after the confirmation of PvCelTOS 
as naturally immunogenic in exposed populations, the present 
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paper describes for the first time the fine B cell epitope mapping 
of a full-length protein. Initially, 10 peptides were specifically 
recognized by naturally acquired antibodies from PvCelTOS 
responders. After a combination of in  silico approaches and 
recognition of overlapped peptides, five immunogenic regions 
were confirmed (PvCelTOS13-33, PvCelTOS73-93, PvCelTOS97-111, 
PvCelTOS127-153, and PvCelTOS181-196) in different frequencies and 
RIs. Moreover, the main linear epitope (ASTIKPPRVSEDAYF) 
presented highest IgG RI and frequency compared to all other 
naturally recognized peptides, suggesting that the majority of 
naturally acquired antibodies against PvCelTOS are directed to 
the C-terminal region. Moreover, T cell responses to PvCelTOS 
may also help to determine the immunodominant repertoire 
in individuals living in malaria-endemic regions, which could 
also supply information for the development of a vaccine for 
PvCelTOS. In humans, PfCelTOS derivate peptides elicited 
proliferative and IFN-γ responses in ex vivo ELISPOT assays 
using peripheral blood mononuclear cells from naturally exposed 
individuals living in Ghana (30).
Recently, CelTOS was demonstrated as highly conserved 
protein across several large groups of apicomplexan parasites 
including Plasmodium spp., Cytauxzoon, Theileria, and Babesia 
and considered essential to cell infection, traversal, and 
membrane disruption (85). Despite the genetical differences 
between PfCelTOS and PvCelTOS, it is important to mention 
that Bergmann-Leitner and colleagues immunized mice and 
rabbits with recombinant PfCelTOS and also observed specific 
antibodies for linear B-cell epitopes at C-terminal (82). These 
observations suggested that CelTOS could present a similar 
conformation among species, with similar regions targeted by 
antibodies. We considered that the exposition of linear epitopes 
is a critical step to their recognition by circulating antibodies; 
therefore, the combination of ESA, molecular dynamics, and 
electrostatic potential surface was used as a complementary 
approach to predict the exposition of epitope sequences on 
protein surface. All immunogenic regions identified were 
exposed and accessible to antibodies. This finding could be 
important in a future subunit vaccine composition based on 
these identified regions. However, the potential of these specific 
antibodies directed main PvCelTOS epitopes in the inhibition 
of sporozoite motility, invasion, and/or traversal remains to be 
investigated.
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FigUre s1 | associations of humoral response and exposition 
parameters in responders to PvcelTOs. (a) Spearman correlation between 
IgG3 reactivity index (RI) and number of recent malaria episodes; (B) Spearman 
correlation between IgG3 and months elapsed since the last malaria episode;  
(c) Spearman correlation between anti-PvCelTOS IgG reactivity index and 
number of previous malaria episodes; and (D) Spearman correlation between 
anti-PvCelTOS IgG RI and months elapsed since the last malaria episode.
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